2024
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
Quiroga D, Wesolowski R, Zelinskas S, Pinette A, Benner B, Schwarz E, Savardekar H, Johnson C, Stiff A, Yu L, Macrae E, Lustberg M, Mrozek E, Ramaswamy B, Carson W. An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer. Cancer Control 2024, 31: 10732748241250189. PMID: 38797949, PMCID: PMC11129578, DOI: 10.1177/10732748241250189.Peer-Reviewed Original ResearchConceptsMetastatic HER2+ breast cancerHER2+ breast cancerStable diseaseBreast cancerCpG-ODNTrastuzumab treatmentTreated patientsHuman epidermal growth factor receptor 2 (HER2)-positiveToll-like receptor 9 agonistHER2-positive breast cancerWeek 2Immune profile changesPeripheral blood mononuclear cellsAdvanced/metastatic breast cancerVEGF-D levelsOpen-label phaseNK cell populationEfficacy of current treatmentsOpen-label studyAggressive breast cancerBlood mononuclear cellsCompared to baselineMedian PFSMetastatic HER2Monocytic MDSCs
2023
Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Bhatia S, Pappo A, Acquazzino M, Allen-Rhoades W, Barnett M, Borinstein S, Casey R, Choo S, Chugh R, Dinner S, Ermoian R, Fair D, Federman N, Folbrecht J, Gandhi S, Germann J, Goldsby R, Hayashi R, Huang A, Huang M, Jacobs L, Lee-Miller C, Link M, Livingston J, Lustberg M, Malogolowkin M, Oeffinger K, Pratilas C, Reed D, Skiles J, von Mehren M, Yeager N, Montgomery S, Hang L. Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 851-880. PMID: 37549914, DOI: 10.6004/jnccn.2023.0040.Peer-Reviewed Original ResearchConceptsYoung Adult OncologyAYA patientsAdult oncologyNCCN guidelinesNCCN Clinical Practice GuidelinesClinical practice guidelinesSupportive care servicesFertility counselingRisk factorsComprehensive carePractice guidelinesCare servicesPatientsOlder adultsOncologyCancerUnique needsGuidelinesAdolescentsBehavioral issuesDiagnosisCareA troubled heart: Mood disorder history longitudinally predicts faster cardiopulmonary aging in breast cancer survivorship
Madison A, Filatov M, Andridge R, Haas G, Povoski S, Agnese D, Lustberg M, Reinbolt R, Wesolowski R, Williams N, Malarkey W, Kiecolt-Glaser J. A troubled heart: Mood disorder history longitudinally predicts faster cardiopulmonary aging in breast cancer survivorship. PLOS ONE 2023, 18: e0283849. PMID: 37000800, PMCID: PMC10065250, DOI: 10.1371/journal.pone.0283849.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsMood disorder historyExercise stress testCancer survivorsCardiovascular diseaseDisorder historyDepressive symptomsTreatment typeEpidemiologic Studies Depression ScaleNon-cancer causesBreast cancer survivorshipStructured Clinical InterviewAdvanced cancer treatmentStress testCardiotoxic treatmentsAdjuvant treatmentCross-sectional relationshipAntidepressant useTrunk fatCVD developmentVisit 1Depression ScaleCancer survivorshipPhysical activityClinical Interview
2022
Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Lockwood B, El-Jawahri A, Walker A, Ehrman S, Russell D, Kale S, Gustin J, Bose-Brill S, LeBlanc T, Luger S, Lustberg M, Bhatnagar B. Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy. Journal Of Adolescent And Young Adult Oncology 2022, 12: 592-598. PMID: 36367711, DOI: 10.1089/jayao.2022.0082.Peer-Reviewed Original ResearchConceptsYoung adultsHigh-risk AMLUnpredictable illness trajectoriesPatient-reported outcomesHospitalized young adultsHighest post-traumatic stress disorderPost-traumatic stress disorderInduction chemotherapyIntensive chemotherapyUnmet psychological needsClinical trialsIllness trajectoryWeek 2Secondary analysisStress disorderOlder adultsPsychological distressLife disruptionChemotherapyWorse qualityAdultsAMLHigh anxietyAnxietyHospitalizationTreatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Network Open 2022, 5: e2244204. PMID: 36445704, PMCID: PMC9709649, DOI: 10.1001/jamanetworkopen.2022.44204.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerErbB2-positive metastatic breast cancerHR-positive metastatic breast cancerLines of therapyMBC subtypesDrug costsBreast cancerMedical costsHuman epidermal growth factor receptor 2 receptor statusMBC treatmentERBB2-negative metastatic breast cancerAssociated direct medical costsEarly-stage breast cancerHormone receptorsFlatiron Health databaseMetastatic recurrence ratesDifferent drug regimensBreast cancer careData of patientsDirect medical costsNovel adjuvant therapySupportive care drugsOutcomes of interestCost-effectiveness analysisAdjuvant therapy
2021
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis
Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, Addison D. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. European Heart Journal 2021, 43: 300-312. PMID: 34791123, PMCID: PMC8914878, DOI: 10.1093/eurheartj/ehab745.Peer-Reviewed Original ResearchConceptsNew-onset atrial fibrillationBreast cancer patientsBreast cancer diagnosisAtrial fibrillationCancer patientsBreast cancer stageRisk factorsBreast cancerCardiovascular mortalityCancer stageCancer diagnosisAF incidenceBreast cancer-related mortalityDevelopment of AFCox proportional hazards modelNew primary diagnosisOnset atrial fibrillationRisk survival statisticsSEER-Medicare analysisCardiovascular risk factorsEnd Results-MedicarePrevalent atrial fibrillationKaplan-Meier methodUnited States cohortCancer-related mortalityErythrocyte Long-Chain ω-3 Fatty Acids Are Positively Associated with Lean Mass and Grip Strength in Women with Recent Diagnoses of Breast Cancer
Belury MA, Cole RM, Andridge R, Keiter A, Raman SV, Lustberg MB, Kiecolt-Glaser JK. Erythrocyte Long-Chain ω-3 Fatty Acids Are Positively Associated with Lean Mass and Grip Strength in Women with Recent Diagnoses of Breast Cancer. Journal Of Nutrition 2021, 151: 2125-2133. PMID: 34036350, PMCID: PMC8349126, DOI: 10.1093/jn/nxab109.Peer-Reviewed Original ResearchConceptsPostprandial energy metabolismGrip strengthAppendicular lean massBreast cancerLean massCardiorespiratory fitnessCancer stageTest mealCancer treatmentPostprandial substrate metabolismBreast cancer survivorsLong-chain omega-3Risk of mortalityFat test mealALM/BMIFatty acidsLong chain ωCross-sectional analysisEnergy metabolismLCn-3PUFACancer survivorsCancer patientsMetabolic outcomesRecent diagnosisSame visitAdverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias
Schnell PM, Lustberg MB, Henry NL. Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias. JNCI Cancer Spectrum 2021, 5: pkab018. PMID: 33842832, PMCID: PMC8023424, DOI: 10.1093/jncics/pkab018.Peer-Reviewed Original ResearchConceptsPatient-perceived benefitsAdverse eventsBrief Pain Inventory-Short FormAromatase Inhibitor–Associated ArthralgiaDuloxetine-treated patientsOriginal primary outcomeDouble-blind trialLow-grade toxicityEffect of duloxetineSubgroup of patientsAverage painComparable patientsAppropriate patientsPrimary outcomeMusculoskeletal symptomsBreast cancerPlaceboDuloxetineSide effectsFunctional assessmentPatientsSecondary analysisFavorable effectTreatmentPerceptions of benefits
2020
Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors
Quick AM, Dockter T, Le-Rademacher J, Salani R, Hudson C, Hundley A, Terstriep S, Streicher L, Faubion S, Loprinzi CL, Coleman JS, Wang KC, Lustberg M. Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors. Maturitas 2020, 144: 37-44. PMID: 33358206, PMCID: PMC7773136, DOI: 10.1016/j.maturitas.2020.10.018.Peer-Reviewed Original ResearchConceptsGynecologic cancer survivorsFemale Sexual Functioning IndexVaginal Assessment ScaleCancer survivorsLaser therapyTreatment armsSexual functionFractional COMedian total FSFI scoreMedian UDI-6 scoreRandomized sham-controlled trialUDI-6 scoresUrinary Distress InventorySerious adverse eventsSham-controlled trialProportion of patientsMedian VAS scoreTotal FSFI scoreFractional CO2 laser therapyCO2 laser therapyLaser treatmentPreliminary evidenceAdenocarcinoma histologyUrinary symptomsAdverse eventsAssociation of pre-existing mental illness with all-cause and cancer-specific mortality among Medicare beneficiaries with pancreatic cancer
Paredes AZ, Hyer JM, Tsilimigras DI, Palmer E, Lustberg MB, Dillhoff ME, Cloyd JM, Tsung A, Ejaz A, Wells-Di Gregorio S, Pawlik TM. Association of pre-existing mental illness with all-cause and cancer-specific mortality among Medicare beneficiaries with pancreatic cancer. Hepato Pancreato Biliary 2020, 23: 451-458. PMID: 32843275, DOI: 10.1016/j.hpb.2020.08.002.Peer-Reviewed Original ResearchConceptsCancer-specific mortalityLong-term outcomesPancreatic cancerMental illnessPre-existing mental illnessSchizophrenic disordersHigh riskMedicare beneficiariesCancer-directed surgerySEER-Medicare databasePre-existing historyAnxiety/depressionEarly-stage cancerCause mortalityMultivariable analysisPancreatic adenocarcinomaStage cancerPsychotic disordersPatientsBipolar disorderIllnessCancerMortalityDisordersDepressionRacial/Ethnic Disparities in Hospice Utilization Among Medicare Beneficiaries Dying from Pancreatic Cancer
Paredes AZ, Hyer JM, Palmer E, Lustberg MB, Pawlik TM. Racial/Ethnic Disparities in Hospice Utilization Among Medicare Beneficiaries Dying from Pancreatic Cancer. Journal Of Gastrointestinal Surgery 2020, 25: 155-161. PMID: 32193849, DOI: 10.1007/s11605-020-04568-9.Peer-Reviewed Original ResearchConceptsEthnic minority patientsPancreatic cancerHospice utilizationMinority patientsHospice servicesWhite patientsMedicare Standard Analytic FilesRacial/Ethnic DisparitiesStandard Analytic FilesDeceased individualsTime of deathOverall low useClinical factorsMost patientsMultivariable analysisAnalytic FilesMedicare beneficiariesPancreatectomyPatientsComparable oddsEthnic disparitiesCancerLogistic regressionLow useDeath
2019
Partnered, adapted argentine tango dance for cancer survivors: A feasibility study and pilot study of efficacy
Worthen-Chaudhari L, Lamantia M, Monfort S, Mysiw W, Chaudhari A, Lustberg M. Partnered, adapted argentine tango dance for cancer survivors: A feasibility study and pilot study of efficacy. Clinical Biomechanics 2019, 70: 257-264. PMID: 31751861, DOI: 10.1016/j.clinbiomech.2019.08.010.Peer-Reviewed Original ResearchConceptsCancer survivorsPostural controlCOP measuresMean satisfaction rateNeurotoxic cancer treatmentsBalance training programPostural control deficitsTango danceHalf of participantsPreliminary efficacySensorimotor trainingNormal rangePromising treatmentPressure measuresQuiet standingSatisfaction rateBalance deficitsCancer treatmentPilot studySurvivorsMore sessionsFeasibility criteriaTango classesControl deficitsMore studies
2018
PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancer
Hou Y, Nitta H, Wei L, Banks P, Lustberg M, Wesolowski R, Ramaswamy B, Parwani A, Li Z. PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancer. The Breast Journal 2018, 24: 911-919. PMID: 30230111, PMCID: PMC6724200, DOI: 10.1111/tbj.13112.Peer-Reviewed Original ResearchConceptsPD-L1 expressionCD8-positive T cellsTumor-infiltrating lymphocytesHER2-positive casesLymph node metastasisCytotoxic immune reactionsBreast carcinomaImmune reactionsNode metastasisPD-L1Immune cellsConventional chemotherapyBreast cancerT cellsTissue microarrayHER2-positive invasive breast cancerHER2-positive invasive breast carcinomasHER2-positive breast cancerHER2-positive breast carcinomasTumor cellsPD1/PD-L1 expressionHigh Nottingham gradePD-L1 stainingInvasive breast cancerLower tumor stageAn Evaluation of Factors Predicting Diet Quality among Cancer Patients
Kane K, Ilic S, Paden H, Lustberg M, Grenade C, Bhatt A, Diaz D, Beery A, Hatsu I. An Evaluation of Factors Predicting Diet Quality among Cancer Patients. Nutrients 2018, 10: 1019. PMID: 30081543, PMCID: PMC6116020, DOI: 10.3390/nu10081019.Peer-Reviewed Original ResearchConceptsHealthy Eating Index 2010Higher HEI scoresCancer patientsHEI scoresDiet qualityMean HEI scoreLower HEI scoresDisease-related factorsDisease-related characteristicsOverall HEI scoreHigher diet qualityTypes of cancerGeneral education diplomaPredictive factorsCancer mortalityPoor-quality dietLower riskPatientsHealthcare providersSpecific demographic characteristicsHigh school degreeDemographic characteristicsOne-way ANOVAScoresCancerDietary Long-Chain n-3 Fatty Acid Intake and Arthritis Risk in the Women’s Health Initiative
Krok-Schoen J, Brasky T, Hunt R, Rohan T, Baker T, Li W, Carbone L, Mackey R, Snetselaar L, Lustberg M, Neuhouser M. Dietary Long-Chain n-3 Fatty Acid Intake and Arthritis Risk in the Women’s Health Initiative. Journal Of The Academy Of Nutrition And Dietetics 2018, 118: 2057-2069. PMID: 29921541, PMCID: PMC6204099, DOI: 10.1016/j.jand.2018.04.005.Peer-Reviewed Original ResearchConceptsArthritis riskRA riskPostmenopausal womenWomen's Health Initiative Observational StudyHealth initiativesDietary long chain nClinical trial cohortProspective cohort studyFood frequency questionnairePrevalence of arthritisFatty acid intakeWomen's Health InitiativeCox regression modelAnti-inflammatory propertiesFatty acidsHistory of arthritisEvidence of benefitRheumatoid arthritis riskLong chain nArthritis outcomesCohort studyFrequency questionnaireHazard ratioIncident osteoarthritisTrial cohort
2017
Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain
Lustberg M, Orchard T, Reinbolt R, Andridge R, Pan X, Belury M, Cole R, Logan A, Layman R, Ramaswamy B, Wesolowski R, Berger M, Patterson E, Loprinzi C, Shapiro C, Yee L. Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain. Breast Cancer Research And Treatment 2017, 167: 709-718. PMID: 29101597, PMCID: PMC5809189, DOI: 10.1007/s10549-017-4559-z.Peer-Reviewed Original ResearchConceptsQuality of lifeJoint symptomsRandomized placebo-controlled pilot trialBrief Pain Inventory-Short FormPostmenopausal breast cancer patientsRed blood cell (RBC) nPlacebo-controlled pilot trialFACT-ES scoresPlacebo-controlled studyPain severity scoreBreast cancer survivorsBreast cancer patientsAnti-inflammatory propertiesAdjuvant AICommon toxicitiesFACT-ESPurposeAromatase inhibitorsPrimary endpointDrug adherencePill countSecondary outcomesMusculoskeletal painTreatment armsCancer survivorsFatty acidsCirculating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer
Wesolowski R, Duggan M, Stiff A, Markowitz J, Trikha P, Levine K, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae E, Lustberg M, Reinbolt R, Mrozek E, Byrd J, Caligiuri M, Mace T, Carson W. Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunology, Immunotherapy 2017, 66: 1437-1447. PMID: 28688082, PMCID: PMC5647220, DOI: 10.1007/s00262-017-2038-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBlack or African AmericanBreast NeoplasmsCell CountChemotherapy, AdjuvantCyclophosphamideCytokinesDoxorubicinFemaleGranulocytesHumansMiddle AgedMonocytesMyeloid-Derived Suppressor CellsNeoadjuvant TherapyPaclitaxelPilot ProjectsTreatment OutcomeWhite PeopleConceptsMyeloid-derived suppressor cellsPathologic complete responseG-MDSC levelsNeo-adjuvant chemotherapyG-MDSCSuppressor cellsComplete responseAnti-HER2 therapyPeripheral blood levelsBreast cancer patientsAfrican American patientsBreast cancer typesCyclophosphamide therapyBlood levelsCancer patientsLast administrationAmerican patientsBreast cancerPatientsFlow cytometryCancer typesChemotherapySignificant riseConfidence intervalsCycle 1Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients
Monfort S, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton M, Loprinzi C, Chaudhari A, Lustberg M. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Research And Treatment 2017, 164: 69-77. PMID: 28374323, PMCID: PMC5510549, DOI: 10.1007/s10549-017-4230-8.Peer-Reviewed Original ResearchConceptsBreast cancer patientsPatient-reported outcomesTaxane-based chemotherapyCancer patientsChemotherapy cyclesEarly-stage breast cancer patientsPatient-reported symptom severityDevelopment of CIPNSubsequent chemotherapy cyclesFirst chemotherapy cyclePatient-reported symptomsDose-limiting toxicityOutpatient oncology clinicsSelf-reported symptomsTaxane infusionTaxane therapyTaxane treatmentCIPN symptomsDose intensityPeripheral neuropathyOncology clinicPatient functionPhysical functionFunctional deficitsGait testing
2016
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair
Villalona-Calero M, Duan W, Zhao W, Shilo K, Schaaf L, Thurmond J, Westman J, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. Journal Of The National Cancer Institute 2016, 108: djv437. PMID: 26848151, PMCID: PMC4948564, DOI: 10.1093/jnci/djv437.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesDiarrheaDrug Administration ScheduleFanconi AnemiaFatigueFeasibility StudiesFemaleGenes, BRCA1Genes, BRCA2Germ-Line MutationHumansMaleMiddle AgedMitomycinNeoplasmsPedigreePoly(ADP-ribose) Polymerase InhibitorsRecombinational DNA RepairThrombocytopeniaConceptsPatient tumorsPARP inhibitorsFunctional deficiencySafety/feasibilityDose-escalation trialBRCA germline mutationsCancer patient tumorsClinical Laboratory Improvement AmendmentsArchival tumor materialCombination armEscalation trialAntitumor responseClinical benefitSevere toxicityTumor specimensPatientsDose levelsSolid tumorsGermline analysisGermline alterationsTumor materialTumorsVeliparibBRCA genesGermline mutations
2015
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary
Mikhail S, Lustberg M, Ruppert A, Mortazavi A, Monk P, Kleiber B, Villalona-Calero M, Bekaii-Saab T. Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. Cancer Chemotherapy And Pharmacology 2015, 76: 1005-1012. PMID: 26416564, DOI: 10.1007/s00280-015-2877-6.Peer-Reviewed Original ResearchMeSH KeywordsActivation, MetabolicAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCapecitabineCarboplatinDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleEnzyme InductionEsophageal NeoplasmsFatigueFemaleGene Expression Regulation, NeoplasticHematologic DiseasesHumansKaplan-Meier EstimateMaleMaximum Tolerated DoseMiddle AgedNeoplasmsNeoplasms, Unknown PrimaryPaclitaxelPancreatic NeoplasmsProdrugsThymidine PhosphorylaseTreatment OutcomeUp-RegulationYoung AdultConceptsAdvanced solid tumorsII studyUnknown primaryDay 1Phase I/II studySolid tumorsPhase IPhase II patientsAntitumor activityObjective response ratePhase II dosePhase II studyMaximal tolerable doseSynergistic antitumor activityCessation of fundingCapecitabine 750Paclitaxel 60Disease stabilizationAcceptable tolerabilityAdvanced adenocarcinomaPartial responseCarboplatin AUCII patientsTolerable dosePatients